Xenon Pharmaceuticals Files for Approval and Advances Azetucalnor Clinical Trials
XENE Xenon Pharmaceuticals Inc
$40.45 +3.27%
View chart & analysis → - 1Xenon Pharmaceuticals submitted a New Drug Application for azetucalnor to treat focal seizures to the US FDA in the third quarter.
- 2Xenon Pharmaceuticals has secured safety and exposure data from over 1,500 patient-years.
- 3Xenon Pharmaceuticals plans to release primary data from the Phase 3 X-NOVA2 study, which has 360 enrolled patients, in December 2026.
So what's the key point?
Xenon Pharmaceuticals has applied to the US government for approval of a new drug to treat seizures. Important research results are scheduled to be released in December 2026.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.